# Atrial Fibrillation Market Size, Cardiac Rhythm Management Trends and Growth Forecast 2026–2034
<h2>Atrial Fibrillation Market Overview Analysis By Fortune Business Insights</h2><h2>Market Summary</h2><p>According to Fortune Business Insights: The global <strong><a href="https://www.fortunebusinessinsights.com/atrial-fibrillation-market-108921">atrial fibrillation (AFib) market</a></strong> was valued at USD 17.24 billion in 2025 and is projected to grow from USD 17.99 billion in 2026 to USD 25.75 billion by 2034, reflecting a compound annual growth rate (CAGR) of 4.59% over the forecast period. This steady expansion is driven by the rising global burden of cardiovascular disease, an aging population, growing awareness in developing nations, and accelerating research and development activity across leading pharmaceutical companies.</p><p>Atrial fibrillation is a cardiac condition characterized by irregular heart rhythm that can lead to blood clot formation. If left untreated, it significantly elevates the risk of stroke and is commonly associated with underlying conditions such as hypertension, atherosclerosis, and cardiomyopathy. According to data cited from the National Center for Biotechnology Information, approximately 37.5 million people globally were living with AFib as of 2021, a figure projected to rise by more than 60% by 2050.</p><p><strong>Get a Sample Research PDF: <a href="https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/108921">https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/108921</a></strong></p><h2>Key Market Drivers</h2><p>The primary catalyst for market growth is the increasing prevalence of cardiovascular disorders alongside a rapidly aging global population. The World Health Organization reported in 2023 that around 1.28 billion adults between the ages of 30 and 79 suffer from hypertension &mdash; a leading risk factor for AFib. Furthermore, the United Nations projects that by 2050, the number of people aged 65 and above will reach 1.6 billion, compounding demand for effective AFib therapies.</p><p>New drug approvals, government initiatives to improve patient access, and a growing focus on innovative therapies &mdash; including human monoclonal antibodies such as abelacimab, a novel dual-acting Factor XI/XIa Inhibitor under development by Anthos Therapeutics &mdash; are further accelerating growth.</p><h2>Market Restraints</h2><p>Despite favorable growth conditions, the market faces headwinds from rising product recalls due to manufacturing quality issues and safety concerns. Notable examples include Sun Pharmaceuticals' 2023 recall of dofetilide capsules citing violations of current good manufacturing practices, and Marlex Pharmaceuticals' recall of digoxin tablets due to label mix-ups. Such incidents erode patient and provider confidence and can redirect demand toward alternative treatment strategies such as catheter ablation.</p><h2>Segmentation Analysis</h2><p><strong>By Drug Class:</strong> Anticoagulants dominate the market, holding a 78.92% share in 2026. This is underpinned by strong clinical guidance &mdash; including the UK's National Institute for Health and Care Excellence (NICE) recommending four direct oral anticoagulants (DOACs) for AFib-associated stroke prevention &mdash; along with a robust pipeline of new drug applications. Antiarrhythmic drugs represent the secondary segment, with growing interest from manufacturers seeking FDA approval for novel therapies such as Eagle Pharmaceuticals' landiolol.</p><p><strong>By Route of Administration:</strong> The oral segment leads with an 84.98% share in 2026, reflecting the wide availability of orally administered anticoagulants and their strong clinical adoption. NHS England reported that an estimated 460,000 patients began taking DOACs since January 2022, preventing approximately 17,000 strokes and 4,000 deaths in England alone. The intravenous segment is expected to grow at a more modest CAGR of 3.6%.</p><p><strong>By Distribution Channel:</strong> Retail pharmacies hold the largest share at 48.03% in 2026, driven by consumer-focused services, cost advantages over online delivery, and expanding physical networks. Online pharmacies are gaining traction due to convenience, competitive pricing, and home delivery benefits.</p><h2>Regional Insights</h2><p><strong>North America</strong> leads all regions with a 38.33% market share in 2025, generating USD 6.61 billion in revenue. The U.S. is the primary contributor, supported by a large geriatric population, high AFib prevalence, and an active regulatory environment for new drug applications.</p><p><strong>Europe</strong> held a 26.07% share in 2025, valued at USD 4.49 billion. Germany and the UK are key markets, driven by aging demographics, cardiovascular disease burden, and biotech investment &mdash; including a USD 47 million Series B raised by Danish firm Acesion Pharma for its AFib therapy, AP31969.</p><p><strong>Asia Pacific</strong> contributed 20.08% of global revenue in 2025 at USD 3.46 billion and is among the fastest-growing regions. By 2050, an estimated 72 million people in the region are projected to develop AFib, presenting significant long-term demand. Japan, China, and India are the key country markets.</p><p><strong>Latin America and Middle East &amp; Africa</strong> collectively account for approximately 15.5% of the global market, with both regions benefiting from government health initiatives and rising awareness of cardiovascular conditions.</p><p><strong>Connect with Our Expert for any Queries:&nbsp;<u><a href="https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/108921">https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/108921</a></u></strong></p><h2>Competitive Landscape</h2><p>The global AFib market is semi-consolidated, with leading players including Bayer AG, Bristol Myers Squibb, Sanofi, Johnson &amp; Johnson, Daiichi Sankyo, Pfizer, and Eisai Co., Ltd. These companies compete through geographic expansion, new drug development, and strategic partnerships. Recent highlights include Bayer AG's expansion of its Phase 3 program for asundexian in late 2023, and Bristol Myers Squibb's Phase 3 Librexia trial evaluating milvexian for stroke prevention in AFib patients.</p><h2>Conclusion</h2><p>The global atrial fibrillation market is on a sustained growth trajectory through 2034, anchored by demographic trends, expanding clinical pipelines, and improved patient access to therapy. While quality control challenges and alternative treatment options pose moderate restraints, the long-term outlook remains robust across all major regions and drug segments.</p>